Taglich Brothers Initiates Coverage on NeoGenomics, Inc.

NEW YORK, NY, Aug 05 (MARKET WIRE) --
Taglich Brothers, Inc. announces it initiated coverage of NeoGenomics,
Inc. (OTCBB: NGNM).

NeoGenomics, Inc., headquartered in Fort Myers, FL, also operates
laboratories in Nashville, TN and Irvine, CA. The company operates "high
complexity" clinical laboratories performing specialized, high-value
genetic tests used in the diagnosis and prognosis of various types of
cancer. In certain types of cancers, the company's tests also help
predict patient responses to various treatments. The company also operates
a contract research organization. The company's facilities are licensed
under all relevant Federal and state laws, and its services qualify for
reimbursement under major government insurance programs, principally
Medicare and Medicaid.

Genetic testing analyzes abnormalities from the cell surface inward,
specifically in chromosomes, genes and DNA. Genetic testing is much more
accurate than traditional clinical laboratory and anatomic pathology
testing and can lead to a definitive diagnosis in 98-99% of cases. The
rapid growth of genetic testing, which is characterized by high revenues
per test and high margins, is reflected in revenue gains experienced by
the company and comparable specialized laboratories. This growth is
attributed to increases in the number of tests developed to analyze genes
discovered to be implicated in cancer, and higher cancer prevalence
stemming from the aging of the population.

The complete 19-page report is available at www.taglichbrothers.com.

Taglich Brothers, Inc. is a full-service broker dealer focused
exclusively on microcap companies. The Company defines the microcap
segment of the equity market as companies with less than $250 million in
market capitalization. Taglich Brothers currently offers institutional
and retail brokerage services, investment banking and comprehensive
research coverage to the investment community.

We do not undertake to advise you as to changes in figures or our views.
This is not a solicitation of any order to buy or sell. Taglich Brothers,
Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a
market maker and does not sell to or buy from customers on a principal
basis. The above statement is the opinion of Taglich Brothers, Inc. and is
not a guarantee that the target price for the stock will be met or that
predicted business results for the company will occur. There may be
instances when fundamental, technical and quantitative opinions contained
in this report are not in concert. We, our affiliates, any officer,
director or stockholder or any member of their families may from time to
time purchase or sell any of the above-mentioned or related securities.
Analysts and members of the Research Department are prohibited from buying
or selling securities issued by the companies that Taglich Brothers, Inc.
has a research relationship with, except if ownership of such securities
was prior to the start of such relationship, then an Analyst or member of
the Research Department may sell such securities after obtaining expressed
written permission from the Director of Research. As of the date of this
report no Taglich Brothers, Inc. employees had a position in the stock of
the Company mentioned in this report: All research issued by Taglich
Brothers, Inc. is based on public information. In June, 2008, the company
paid a monetary fee of US$6,000, representing payment for the first three
of 12 months, for the creation and dissemination of research reports. From
September, 2008 through May, 2009, the company will pay a monthly monetary
fee of US$2,000, for a total one-year fee of US$24,000 for the creation
and dissemination of research reports.

For further information and Taglich Brothers, Inc. ownership data please
refer to each individual report.

Contact:
Richard Oh
Taglich Brothers, Inc.
631-757-1500

Copyright 2008, Market Wire, All rights reserved.

-0-